Q
QuantAbundance

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

30,827 signal articles · 152 in last 24h · 157,083 total before filter · latest 43m ago
152last 24h
864last 7d
147● bullish (7d)
80● bearish (7d)
214publishers
AllMacro193Earnings132M&A101Regulatory19Product20Analyst23
✕ clear all filterssentiment: bearishSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
SELLAS Life Sciences Group (SLS) Nears REGAL Analysis, Is The Stock Too Expensive?
Simply Wall St.55d agobearish
SELLAS Life Sciences Group (SLS) Nears REGAL Analysis, Is The Stock Too Expensive?

SELLAS Life Sciences Group (SLS) is back in focus as its Phase 3 REGAL trial in acute myeloid leukemia nears final analysis and Daiwa Securities reports a very large increase in its shareholding. See our latest analysis for SELLAS Life Sciences Group. The recent clinical update and Daiwa’s larger stake come after a sharp move in SELLAS Life Sciences Group’s share price, with a 1-day share price return of 12.09% and a year-to-date share price return of 157.93%, while the 1-year total...

BWX Technologies (BWXT) Sells Medical Business And Signs New Thorium Fuel Deal
Simply Wall St.55d agobearish
BWX Technologies (BWXT) Sells Medical Business And Signs New Thorium Fuel Deal

BWX Technologies (NYSE:BWXT) has agreed to sell its medical business to Nordic Capital, while keeping a minority interest and technical involvement. The company has also signed a fuel fabrication agreement with Clean Core Thorium Energy related to future nuclear fuel deployments. These moves indicate a shift in BWX Technologies’ business mix toward core nuclear operations and advanced fuel capabilities. BWX Technologies enters these transactions with a share price of $173.79 and a 5 year...

SELLAS Life Sciences Group (SLS) Stock Looks Priced At A Premium
Simply Wall St.55d agobearish
SELLAS Life Sciences Group (SLS) Stock Looks Priced At A Premium

SELLAS Life Sciences Group has delivered a very large 3 year return, yet its recent share price swings and a low overall value score suggest the stock may now be pricing in a lot of optimism. The stock has returned about 6.1x over the past 3 years, which sets a high bar for any further upside to be justified by fundamentals. Future clinical and commercial progress can support the current valuation, but execution risk and funding needs typical for early stage biopharma may limit how much...

NRG Energy (NRG) Misses Q2 Earnings Estimates
Zacks55d agobearish
NRG Energy (NRG) Misses Q2 Earnings Estimates

NRG (NRG) delivered earnings and revenue surprises of -10.24% and +27.02%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

DigitalOcean (NYSE:DOCN) Exceeds Q2 CY2026 Expectations But Stock Drops 10.9%
StockStory55d agobearish
DigitalOcean (NYSE:DOCN) Exceeds Q2 CY2026 Expectations But Stock Drops 10.9%

Cloud computing platform DigitalOcean (NYSE:DOCN) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 28.6% year on year to $281.2 million. Guidance for next quarter’s revenue was better than expected at $305.5 million at the midpoint, 1.9% above analysts’ estimates. Its non-GAAP profit of $0.45 per share was 72.9% above analysts’ consensus estimates.

Spotify Shares Slide After Second-Quarter Earnings Miss
InvestorsHub55d agobearish
Spotify Shares Slide After Second-Quarter Earnings Miss

Spotify Technology SA (NYSE:SPOT) shares fell around 6% in pre-market trading after the music streaming platform reported second-quarter 2026 results that missed Wall Street expectations, despite continued growth in subscribers and record gross margins. While the company delivered solid user growth and issued stronger-than-expected revenue guidance for the current quarter, weaker earnings weighed on investor sentiment.

Investing.com55d agobearish
JPMorgan cuts Nike to Underweight, sees EPS well below consensus

Investing.com -- JPMorgan downgraded Nike to Underweight from Neutral in a note Tuesday, warning investors that the financial impact of the company's turnaround decisions will linger far longer than the Street expects, pressuring earnings through fiscal 2028.